. For the duration of the study period, we had a positive margin and our reimbursement to charge rate for multiple myeloma patients was close to MDACC goal of 55%, with 53.3% rate overall. Based on this analysis, there were some differences between the model assumptions and our findings from actual data. Our model had predicted 100% usage for the FDA approved indication of multiple myeloma in the expected patient population of 25 patients. Actual data collected showed that not only did we have more than expected number of patients on bortezomib, potentially due to the change in labeling to an earlier stage of disease, but our model had assumed 4 cycles of bortezomib therapy per patient whereas the actual average number of cycles per patient was only 2 at our institution. We did not have data to determine whether the patients had obtained more cycles of therapy from other providers. Lessons Learned: Annual budget impact analysis helped estimate the cost to the institution for adding bortezomib to the formulary. Performing an annual budget impact before the addition of a drug to an institution's formulary, and comparing it with the annual budget impact after a few years of the drug being on the formulary, is an essential process in determining the best use of scarcely available, expensive resources for the most appropriate use. Cost effectiveness studies, that take costs of treatments and their outcomes in patients into account, are as important in allocating resources to best possible use in this era of rising costs and future research will focus on calculating cost-effectiveness specifically for the institution's patient population. With the fast pace of new medical technologies launched into the market, it is imperative to develop a formal and methodical approach to assess and evaluate outcomes and impacts; one that goes beyond the short-term vision of price and volume negotiation. Although there are several agencies across the globe that evaluate technologies, not always the market can count on their results because 1) either these reports are based on scenarios that don't reflect the real situation (for instance, a health plan in Africa considering a report about the U.S. medical system), or 2) there is not enough time to wait for a conclusion. Goals: Effective coverage and Reimbursement decisions must reflect the local scenarios where they happen, and new methods to evaluate medical technologies must be in place to allow distant markets to reach their own conclusions about health care. One proposed answer to this problem is to bring different market stakeholders to teamwork and develop an approach that combines everyone's expertise into an effective methodology reflecting the local market scenario and population. In summary, to develop a Health Technology Assessment that reflects the local health care scenario and that is agile enough for a Health Plan. Outcomes items used in the decision: Cost-effectiveness data (literature and local), local prevalence and incidence disease rates. Lessons Learned: Developing nations cannot count solely on studies performed in developed countries; they must develop analyses that reflect local scenarios and markets. To improve value for patients, one stakeholder cannot act alone. All participants must take action to improve the health care system's efficiency.
FDA-approved in December 2006, during our study period. We also reviewed charges and reimbursement data collected for the drug from June 2006 to December 2006. For the duration of the study period, we had a positive margin and our reimbursement to charge rate for multiple myeloma patients was close to MDACC goal of 55%, with 53.3% rate overall. Based on this analysis, there were some differences between the model assumptions and our findings from actual data. Our model had predicted 100% usage for the FDA approved indication of multiple myeloma in the expected patient population of 25 patients. Actual data collected showed that not only did we have more than expected number of patients on bortezomib, potentially due to the change in labeling to an earlier stage of disease, but our model had assumed 4 cycles of bortezomib therapy per patient whereas the actual average number of cycles per patient was only 2 at our institution. We did not have data to determine whether the patients had obtained more cycles of therapy from other providers. Lessons Learned: Annual budget impact analysis helped estimate the cost to the institution for adding bortezomib to the formulary. Performing an annual budget impact before the addition of a drug to an institution's formulary, and comparing it with the annual budget impact after a few years of the drug being on the formulary, is an essential process in determining the best use of scarcely available, expensive resources for the most appropriate use. Cost effectiveness studies, that take costs of treatments and their outcomes in patients into account, are as important in allocating resources to best possible use in this era of rising costs and future research will focus on calculating cost-effectiveness specifically for the institution's patient population. 
Problem or Issue Addressed:
With the fast pace of new medical technologies launched into the market, it is imperative to develop a formal and methodical approach to assess and evaluate outcomes and impacts; one that goes beyond the short-term vision of price and volume negotiation. Although there are several agencies across the globe that evaluate technologies, not always the market can count on their results because 1) either these reports are based on scenarios that don't reflect the real situation (for instance, a health plan in Africa considering a report about the U.S. medical system), or 2) there is not enough time to wait for a conclusion. Goals: Effective coverage and Reimbursement decisions must reflect the local scenarios where they happen, and new methods to evaluate medical technologies must be in place to allow distant markets to reach their own conclusions about health care. One proposed answer to this problem is to bring different market stakeholders to teamwork and develop an approach that combines everyone's expertise into an effective methodology reflecting the local market scenario and population. In summary, to develop a Health Technology Assessment that reflects the local health care scenario and that is agile enough for a Health Plan. Outcomes items used in the decision: Cost-effectiveness data (literature and local), local prevalence and incidence disease rates. 
Results:
The core Recommendations will be presented along with their rationale, interpretation and use in guiding decision makers. A worked out example will be used to illustrate the implications. Lessons Learned: It is possible to develop Methods that provide for economic evaluation within the constraints posed in Germany. This is done by focusing on the narrower objective of efficiency within a therapeutic area rather than the much loftier goal of relative valuation across the health care system. 
PCASE6 HOW SHOULD NEW TECHNOLOGIES AND NEW DEVICES BE

